Breast Cancer Awareness Month - the evolving role of ADCs

In this week’s VJOncology podcast, leading experts share the latest updates in ADCs in HER2-positive and metastatic breast cancer in recognition of Breast Cancer Awareness Month. Charles Geyer, MD, discusses pivotal results from the Phase III DESTINY-Breast05 trial, where trastuzumab deruxtecan (T-DXd) significantly improved invasive disease-free and disease-free survival versus trastuzumab emtansine (T-DM1) in high-risk HER2-positive early breast cancer, reducing the risk of brain metastases. Sara Tolaney, MD, MPH, highlights the practice-changing reduction in recurrence risk with T-DXd and comments on the expanding role of antibody–drug conjugates (ADCs) in earlier lines of therapy across breast cancer subtypes, referencing data from DESTINY-Breast09 and ASCENT-03. Finally, Erika Hamilton, MD, reviews the advancement of ADCs into the curative setting through DESTINY-Breast11 and discusses emerging combination strategies and first-line use in triple-negative breast cancer, emphasizing the growing importance of ADCs in modern breast cancer care.